Platelet granule secretion machinery and phospholipase A2

Platelet granule secretion machinery and phospholipase A2 (PLA2) are essential components of the platelet activation cascade required for effective hemostasis and pathological thrombosis [PubMed: 28611155]. Phospholipase A2, particularly the cytosolic form (cPLA2α), catalyzes the release of arachidonic acid from the plasma membrane, which is the precursor for thromboxane A2 synthesis, a key driver of platelet recruitment [UniProt: P47712]. The granule secretion machinery involves a coordinated assembly of SNARE proteins (such as VAMP-8, Syntaxin-11, and SNAP-23) and priming proteins like Munc13-4 that facilitate the fusion of alpha and dense granules with the platelet surface [PubMed: 24101516]. This exocytosis process releases critical molecules like ADP, von Willebrand factor, and P-selectin, which amplify the clotting response and mediate interactions with the vascular wall [PubMed: 10610117]. Dysregulation of these pathways is central to the development of cardiovascular diseases, including myocardial infarction and ischemic stroke. Consequently, these proteins are major targets for pharmacological intervention aimed at reducing platelet hyper-reactivity while balancing the risk of bleeding [PubMed: 21148301].

Other names

Platelet exocytosis machinerycPLA2Platelet secretory pathwaySNARE complex

Inhibition of arachidonic acid release from membrane phospholipids and blockade of pro-thrombotic mediator exocytosis from platelet granules.